RECEIVED
CENTRAL FAX CENTER

MAR 2 4 2004

OFFICIAL

MARSHALL, GERSTEIN & BORUN LLP
ATTORNEYS AT LAW
6300 SEARS TOWER
233 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606-6357
(312) 474-6300
FAX: (312) 474-0448

March 24, 2004

### FACSIMILE TRANSMISSION SHEET

TO

**COMPANY** 

USPTO

FAX NO.

1-703-872-9306

PHONE NO.

FROM: Sharon M. Sintich

EXTENSION:

818

PAGES (INCLUDING THIS PAGE):

12

**CLIENT NO:** 

29915

MATTER NO:

6280M

PLEASE CONFIRM RECEIPT:

Yes

**COUNTRY CODE:** 

US

MESSAGE:

Please contact Jill L. Schumerth at (312) 474-6818 if you do not receive all of the pages in good condition.

\*\*\*\*\*\*

This transmission contains confidential information intended only for the addressee. If you are not the addressee, any disclosure or use of this information by you is strictly prohibited. If you have received this facsimile in error, please notify us by telephone immediately.

PTO/SB/21 (08-03 Approved for use through 07/31/2006. OMB 0651-003* U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number					
TRANSMITTAL		Application Number	09/869,414	.1	
		Fillng Date	June 27, 20	01	
FORM		First Named Inventor	Mark E. Gui	Mark H. Gurney	
(to be used for all correspondence after initial filling)		Art Unit	1647		
, , , , , , , , , , , , , , , , , , , ,		Examiner Name	C. Nichols		
Total Number of Pages in This Submission 1		Attorney Docket Numb	<sup>ber</sup> 29915/6280M		
ENCLOSURES (Check all that apply)					
X Fee Transmittal Form	Drawing(s)		After Allowance Communication		
Fee Attached	Licensing-rel	ated Papers		nunication to Board of	
Amendment/Reply	Petition		ET Appeal Comm	unication to Group Brief, Reply Brief)	
After Final	onvert to a pplication	Proprietary Information			
Affidavits/declaration(s)	Affidavits/declaration(s)  Power of Attorney, Revocation Change of Correspondence Address				
Extension of Time Request X Terminal Dis		tlaimer (2)	Other Enclosure(s) (please identify below):		
Express Abandonment Request Request for		Refund			
X Information Disclosure Statement CD, Number of		of CD(s)			
Certified Copy of Priority Document(s)					
Response to Missing Parts/ Incomplete Application					
Response to Missing Parts under 37 CFR 1.52 or 1.53					
		·			
SIGNATURE OF APPLICANT, ATTORNEY, OR ACIENT					
Firm MARSHALL, GERSTEIN & BORUN LLP Sharon M. Sintich - 48,484					
Signature Alana Manager					
Date March 24, 2004					
I hereby certify that this correspondence is being facsimile fransmitted to the Patent and Trademark Office, facsimile no. (703) 872- 9306, on the date shown below.					
Dated: Merch 24, 2004 Signature: (Sharon M. Sintich)					

PTO/3B/17 (10-03)
Approved for use through 7/31/2005. OMB 0351-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Complete if Known FEE TRANSMITTAL 09/869,414 Application Number June 27, 2001 Filing Date for FY 2004 Mark E. Gumey First Named Inventor Effective 10/01/2003, Patent fees are subject to annual revision C. Nichols Examiner Name 1647 Applicant claims amall entity status. See 37 CFR 1.27 Art Unit 29915/6280M TOTAL AMOUNT OF PAYMENT Attorney Docket No. METHOD OF PAYMENT (check all that apply) FEE CALCULATION (continued) 3. ADDITIONAL FEES Check Deposit Account Large Entity Small Entity 13-2855 Féo Fee (S) Fcc Account Number Fee Description Fee Paid Deposit MARSHALL, GERSTEIN & 1051 130 2051 Surchargs - late filing (se or oath Account **BORUN LLP** Surcharge - late provisional filing fee or cover 1052 50 2052 25 The Director is authorized to: (check all that apply) shect. X Credit any overpayments 1053 Charge fee(s) indicated below 1053 130 Non-English specification 1812 1812 Charge any additional fee(s) or any underpayment of fee(s) Requesting publication of SIR prior to Examiner action 1804 920 1804 820 Charge fee(s) indicated below, except for the filling fee Requesting publication of SIR after Examiner action to the above-identified deposit account. 1805 1.840 1805 **FEE CALCULATION** 1251 110 2251 Extension for reply will in first month 420 2252 1. BASIC FILING FEE 1252 Extension for reply within second month Large Entity Small Entity 1259 950 2259 475 Extension for reply within third month Fee (\$) Fee (\$) Fee Description Fee Pald 1254 1,490 2254 740 Extension for repty within fourth month 2255 770 385 Utility filing fee 1255 2,010 1,005 Extension for reply within fifth month 1401 2401 1002 340 2002 170 Design filing (cc 330 185 Notice of Appeal 2003 265 1402 1003 530 Plant filing fee 330 2402 Filing a brief in support of an appeal 1004 770 2004 385 Reissue filing fee 1403 290 2403 1451 1,510 Petition to institute a public use proceeding 2005 1,510 1451 1452 2452 110 Petition to revive - unavoidable SUBTOTAL (1) (5) 1453 1,330 2453 Petition to revive - unincentional 2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE 1501 1,330 2501 665 Utility Issue fee (or reinnue) Evira Fee from 1502 480 2502 Dasign issue fee Fee Paid Total Claims 1503 640 2503 920 Plant issue fee independent 1460 130 1460 130 Petitions to the Commissioner Procession fee under 17 CFR 1.17(a) Multiple Dependent 1807 50 1807 1806 150 1806 180 Submission of Information Disclosure Start 180.00 Large Entity | Small Entity Recording each patent assignment per property (I)mes number of properties) Fee Çode Fee (\$) Fee (5) 8021 8021 40 40 Fee Description Code Filling a submission after final rejection (37 CFR 1.129(a)) 1202 18 2202 Claims in excess of 20 1809 770 2809 385 86 2201 1201 Independent claims in excess of 3 For each additional invention to be 770 2810 385 1810 1203 290 2203 145 Multiple dependent claim, if not paid examined (37CFR 1.129(b)) \*\* Reissue independent claims over original patent 1204 86 2204 1601 770 2601 385 Request for Continued Examination (RCE) Request tor expedited examination of a design application 900 900 1602 \*\* Reissue claims in excess of 20 2205 1205 18 and over original patent 220.00 Statutory (bisclaimer (2) 1814 Other fee (specify) SUBTOTAL (3) (5) 400.00 SUBTOTAL (2) (3) \*Reduced by Basic Filing Fee Pald 0.00 \*\*or number previously paid, if greater; For Reissues, see above SUBMITTED BY (Compleio (d applicable)) Registration No. 48,484 Telephone (312) 474-6631 Sh**∯**ron M. Sintich Name (Print/Type) March 24, 2004 thereby certify that this correspondence is being facsimile transmitted to the Patent and Trademark Office, facsimile no. (703) 872-9306, on the date shown below. Dated: March 24, 2004 Signature: \_\_

I hereby certify that this paper and pupers referred to as being attached, are being transmitted via facsimile (Fax No. 703-872-9306) to the Commissioner for Patents, Alexandria VA, 22313, on

Dated: March 24, 2003

Docket No.: 29915/6280M

(PATENT)

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Mark E. Gurney, et al.

Application No.: 09/869,414

Group Art Unit: 1647

Filed: June 27, 2001

Examiner: C. Nichols

For:

ALZHEIMER'S DISEASE SECRETASE, APP

SUBSTRATES THEREFOR, AND USES

**THEREFOR** 

# SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

The above-identified application is a member of a family of co-pending U.S. applications (the "Asp2" applications). This Information Disclosure Statement describes the family of applications for the Examiner.

## I. Prosecution Strategy

A multi-application filing strategy was initiated to expedite prosecution of the Asp2 patent applications. Petitions to make special require restriction to a single invention. It was predicted that the originally filed claims in 09/416,901 would be restricted into at least 5 claim groups (human Asp2 polynucleotides, human Asp2 polypeptides, methods of screening, murine Asp2 polynucleotide and polypeptide sequences, and methods of using antisense oligonucleotides). Therefore, 10 divisional applications were filed in April, 2000 wherein these 5 claim groups were each presented in two divisional applications. Petitions to make special were filed in five of the divisional applications (one for each claim set). Because of antidotal evidence that petitions to make special will sometimes actually slow prosecution, five identical applications were filed without petitions.

Application No.: 09/869,414

The American Inventor's Protection Act of November 29, 2000 created new provisional rights in the United States based on a published application. Therefore, five additional divisional applications were filed in February, 2001 for the purpose of publication in the United States. Since the speed at which the U.S. PTO would publish these applications was uncertain, three PCT applications were filed with the International Bureau with a request for expedited publication in May, 2001. The present application is a national phase application of one of these PCT applications. These steps were taken to have an application publish and be effective in the U.S. for provisional rights as soon as possible.

### II. Related Pending Applications

Submitted herewith, as Appendix A and Form PTO-1449, is list of pending U.S. patent applications that are related to the above-identified application. The related applications claim priority to U.S. provisional applications 60/101,594 and 60/155,493, and U.S. application 09/404,133 (abandoned). One or more of the related applications may contain claims that are similar in scope or content to claims of the present application. Copies of these applications are not enclosed, but are pending in the U.S. Patent Office and should be available to the Examiner.

These pending applications are currently under examination by Examiners Sharon Turner, Olga Chernyshev or Elizabeth Slobodyansky. Examiners Turner and Chernyshev, both of whom have examined multiple applications of the family, have been made aware of the size and complexity of the patent family on an informal basis. As this is the present examiner's first exposure to the patent family, this statement is submitted to assist him in understanding the patent family.

The elected claims in the present invention are directed to polynucleotides of SEQ ID NO: 3, the polypeptides (SEQ ID NO: 4) encoded thereby and methods of using these polynucleotides and polypeptides. The following related pending U.S. applications contain claims directed to SEQ ID NO: 3, SEQ ID NO: 4 and/or methods of screening using the polynucleotides or polypeptides: 09/548,368, 09/548,365, 09/548,366, 09/549,369, 09/794,743, 09/794,927, 09/794,847, and 09/794,925.

During the course of prosecution of these applications, different examiners have raised a variety of rejections under 35 U.S.C. §102, §103, §112, first and second paragraphs, and double patenting. Upon request, the Applicants will provide the Examiner

Application No.: 09/869,414

with copies of office actions and/or responses filed for the related applications. The Examiner is invited to contact the undersigned if further explanation of the patent family is necessary.

#### III. Conclusion

This Supplemental Information Disclosure Statement is being submitted after receipt of the first office action on the merits. Please charge the fee (\$180.00) due under 37 C.F.R. §1.97 (c) to Deposit Account No. 13-2855. The Commissioner is authorized to charge any additional fees due with this Statement to the above-identified Deposit Account.

Dated: March 24, 2004

Respectfully submitted,

Sharon M. Sintich

Registration No.: 43,484

MARSHALL, GERSTEIN & BORUN

233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357

(312) 474-6300

Agents for Applicant